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Abstract
Type 1 narcolepsy is caused by deficiency of hypothalamic orexin/hypocretin. An autoim-
mune basis is suspected, but no specific antibodies, either causative or as biomarkers,
have been identified. However, the AS03 adjuvanted split virion H1N1 (H1N1-AS03) vac-
cine, created to protect against the 2009 Pandemic, has been implicated as a trigger of nar-
colepsy particularly in children. Sera and CSFs from 13 H1N1-AS03-vaccinated patients
(12 children, 1 young adult) with type 1 narcolepsy were tested for autoantibodies to known
neuronal antigens including the N-methyl-D-aspartate receptor (NMDAR) and contactin-
associated protein 2 (CASPR2), both associated with encephalopathies that include
disordered sleep, to rodent brain tissue including the lateral hypothalamus, and to live
hippocampal neurons in culture. When sufficient sample was available, CSF levels of mela-
nin-concentrating hormone (MCH) were measured. Sera from 44 H1N1-ASO3-vaccinated
children without narcolepsy were also examined. None of these patients’ CSFs or sera was
positive for NMDAR or CASPR2 antibodies or binding to neurons; 4/13 sera bound to
orexin-neurons in rat brain tissue, but also to other neurons. MCH levels were a marginally
raised (n = 8; p = 0.054) in orexin-deficient narcolepsy patients compared with orexin-nor-
mal children (n = 6). In the 44 H1N1-AS03-vaccinated healthy children, there was no rise in
total IgG levels or in CASPR2 or NMDAR antibodies three weeks following vaccination. In
conclusion, there were no narcolepsy-specific autoantibodies identified in type 1 narcolepsy
sera or CSFs, and no evidence for a general increase in immune reactivity following H1N1-
AS03 vaccination in the healthy children. Antibodies to other neuronal specific membrane
targets, with their potential for directing use of immunotherapies, are still an important goal
for future research.
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Introduction
Narcolepsy is a lifelong and disabling condition, first described over 130 years ago [1]. It is
characterised by dysregulation of the sleep-wake cycle with inappropriate penetration of rapid
eye movement (REM) sleep, and cataplexy, a sudden loss of motor tone triggered by emotion.
Type 1 narcolepsy[2] is associated with a selective loss of neurons secreting neuropeptides
orexin A and B, also called hypocretins 1 and 2 [3]. The disease is diagnosed from the history
of severe sleepiness, in addition to the co-existence of cataplexy, and a positive multiple sleep
latency test (MSLT), or very low or absent CSF orexin [4].
A tightly-linked HLA association is well established [5]. Twin discordance,[6] and the asso-
ciation of onset with streptococcal infection [7] and pandemic flu immunisation [8] suggest an
immunological trigger. In addition to the DQB106:02 association, [9] genome-wide associa-
tion studies found polymorphisms in the T cell receptor alpha [10] as well as other immunity-
linked genes. Antibodies to various CNS proteins, or candidate antigens, have been identified
in narcolepsy using a variety of approaches, but none have yet led to development of disease-
specific antibody tests (reviewed in [11–13]), and immunotherapies have produced variable re-
sults (reviewed in [13]).
Sleep disturbance is a common features of autoimmune forms of encephalitis associated
with antibodies to the voltage-gated potassium channel (VGKC) complex proteins, contactin-
associated protein 2 (CASPR2), or leucine- rich glioma-inactivated 1 (LGI1), or to N-methyl-
D-aspartate receptor (NMDAR) which are all proteins exposed on the surface of live neurons
(reviewed in [14]).
The recent recognition of children with narcolepsy and cataplexy, both presenting within
months of Pandemrix vaccination (AS-03 adjuvanted) against the Pandemic 2009 H1N1 Swine
Flu (H1N1-AS03), especially in northern European countries, [8, 15–18], provided an opportu-
nity to look for potentially pathogenic antibodies in sera and CSFs close to onset. In addition,
sera from healthy children before and after H1N1-AS03 vaccination [19] were examined for
changes in total IgG and for CASPR2 and NMDAR antibodies.
Methods
Ethics statement
The sera and CSFs from narcolepsy patients were obtained with ethical permission and written
informed consent from subjects or their parents with approval of the coordinating Ethical
Boards of the University Hospital of Gothenburg and the Hospital District of Helsinki and
Uusimaa. The study of H1N1 vaccination sera [19] was approved by the Oxfordshire Research
Ethics Committee A (No 09/H0604/107), and the UKMedicines and Healthcare Products Reg-
ulatory Agency (EUDRACT 2009-014719-11).
All animal procedures were carried out in accordance with the UK Home Office guidelines
under a project license granted by the Home Office to AV (Immunity in Neurological and De-
velopmental Disorders, PPL No 30/1890). The adult rats were PBS-perfused under terminal
barbiturate anaesthesia, and the newborn pups sacrificed by decapitation (Schedule 1). Com-
pliance to rules and regulations and adherence to the 3Rs principles was monitored by Biomed-
ical Services, University of Oxford and Home Office inspectors.
Post H1N1-AS03 vaccination narcolepsy samples
The initial cohort was composed of 14 serum/CSF pairs from Swedish and Finnish patients
from whom the initial association of narcolepsy after vaccination with Pandemrix were identi-
fied (Table 1) as described in detail elsewhere [17]. All were DQB106:02 positive. Sera from 15
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children, including five who had had H1N1 vaccination but had normal hypocretin/orexin lev-
els were used as controls. CSF orexin levels were measured using a commercially available
radioimmunoassay (Phoenix Peptides, Arizona, USA). MCH levels were also measured by
radioimmunoassay (Phoenix Peptides, Arizona, USA), but to ensure levels were within the lin-
ear range, 40 pg of the MCH standard was added before testing to each 100 μl sample (to give a
Table 1. Narcolepsy patient demographics and results of antibodies to neuronal antigens.
Patient Sex,
age (y),
time
since
onset
(m)
CSF orexin
A, MCH
(pg/ml)
NMDAR
(1:20)
CASPR2
(1:100)
LGI1
(1:20)
Contactin2
(1:100)
Dopamine
D2 (1:20)
GABAA3
(1:20)
Immuno-
ﬂuorescence
Tissue
sections
Immuno-
ﬂuorescence
Live
hippocampal
neurons
1 F,16, 13 <10, n.d. 0 0 0 0 0 0 0 0
2 F,15, 13 <10, 133 0 0 0 0 0 0 0 0
3 M, 4,16 <10, n.d. 0 0 0 0 0 0 0 0
4 M, 9, 10 52, n.d. 0 0 0 0 0 0 0 0
5 F, 8, 7 <10, n.d. 0 0 0 0 0 0 0 0
6 M, 11,
14
<10, 141 0 0 0 0 0 0 0 0
7 M, 12,
12
<10, 263 0 0 0 0 0 0 0 0
8 M, 16, 7 <10, 217 0 0 0 0 0 0 2 0
9 M, 14,
16
<10, n.d. 0 0 0 0 0 0 2 0
10 M, 18,
13
<10, 246 0 0 0 0 0 0 0 0
11* M, 24,
41
<10, 198 0 0 0 0 0 0 0 0
12 F, 18,
20
<10, n.d. 0 1 0 0 0 0 2 0
13 M, 17,
19
55, 298 0 0 0 0 0 0 1 0
All
narcolepsy
patients
(n = 13)
Orexin
<110 pg/ml
(n = 13),
MCH 213
+/- 57 pg/ml
(n = 8)
0/13 1/13 0/13 0/13 0/13 0/13 4/13 0/13
Orexin
normal
paediatric
sera/CSFs
(n = 15)
Orexin
>200 pg/ml
(n = 15),
MCH 156
+/- 38 pg/ml
(n = 6)
0/15 0/15 0/15 0/15 0/15 0/15 0/15 0/15
CSF orexin levels <110 pg/ml supports a diagnosis of type 1 narcolepsy (narcolepsy with cataplexy). MCH levels were measured in CSFs the CSFs that
were still available and in one additional narcolepsy CSF (without a paired serum). Serum cell-based assays for antibodies to individual antigens,
immunoﬂuorescence for binding to orexin neurons on rodent brain tissue sections or to hippocampal neuronal cultures were scored subjectively by
comparison with positive and negative controls: 0 = no binding, 1 = weakly positive, 2 = moderately positive, 3 = strongly positive, 4 = complete co-
localisation.
*In patient 11 the onset of narcolepsy was 18 months before Pandemrix vaccination but his cataplexy worsened after vaccination. In all other cases the
onset of symptoms was after Pandemrix vaccination.
doi:10.1371/journal.pone.0129555.t001
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final concentration of>400 pg/ml). Results were read from the standard curve (calculated by
Graphpad Prism 5), and presented after subtraction of 40 pg for each sample.
Pre and post vaccination healthy paediatric samples
Sera were obtained from 42 participants before and 3 weeks after 2 doses of an AS03-H1N1
adjuvanted split-virion vaccine (Pandemrix, GlaxoSmithKline, Rixenstart, Belgium). These
samples had originally been obtained to investigate H1N1 seroconversion rates following vacci-
nation [19].
Serum IgG concentration
Serum IgG was measured by western blot using 10 μl of a 1:300 dilution of serum and detecting
with peroxidase-labelled anti-human IgG. The blots were scanned and densitometric analysis
performed of the 50 kDa IgG heavy chain; IgG levels were calculated by comparison with a
human IgG heavy chain standard curve.
Antibody assays to detect specific neuronal surface antibodies
Cell-based assays (eg.[20]) were used to measure antibodies to the VGKC-complex compo-
nents, contactin2, CASPR2 (sera diluted 1:100) and LGI1, NMDAR, GABAA3 and dopamine
(D2R) receptors (sera diluted 1:20). CSFs were tested at 1:1. The test samples were coded and
mixed randomly with other samples for all tests. Binding of IgG antibodies to the surface of the
antigen-expressing cells was detected with Alexa Fluor 568 (red) anti-human IgG (Invitrogen,
UK). Results were scored by ST and one independent observer, in a double-blinded manner,
according to a subjective but reproducible scale (0 = none, 1 = weak, 2 = moderate, 3 = strong,
4 = very strong; see [20]) and by comparison with positive and negative controls.
Immunohistochemistry on rat brain frozen sections
Coronal hypothalamic 12 μm sections were made from snap-frozen brains of adult rats. They
were subsequently, dried, fixed in 3% formaldehyde (1 minute, room temperature), and
blocked in 10% foetal calf serum (1 hour, room temperature). The orexin neurons were first lo-
calised with anti-orexin-A antibody (Phoenix Pharmaceuticals, California, USA 1:150, over-
night at 4°C). To detect binding of autoantibodies, sera (1:300) or CSFs (1:1) were applied
overnight at 4°C, followed by Alexa Fluor 488 anti-human IgG (Invitrogen; 1 hour, room tem-
perature). All steps were separated by three 1 min washes in phosphate-buffered saline (PBS).
Coverslips were mounted onto slides with DAPI supplemented fluorescence mounting media,
and observed by indirect immunofluorescence. Antibody binding was subjectively quantified
as above. Following this initial screen, samples which gave positive staining were investigated
further by testing after adsorption with pigeon acetone liver powder in order to remove any an-
tibodies against non-CNS rat epitopes [21].
Binding to live rat hippocampal neurons
Using established methods [20], neurons were prepared from P0 (newborn) rat pups. After 12
days in culture, coverslips with neuronal cultures were incubated with patient serum (1:100)
and binding to the live neurons visualised by fixation and detection with Alexa Fluor 488
(green) as described previously. Any binding was scored subjectively in relation to a panel of
healthy and positive controls.
Neuronal Antibodies in Narcolepsy after H1N1-AS03 Vaccination
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Results
Clinical and CSF orexin data on patients
Clinical information and follow-up were only released after the orexin levels and antibody data
were obtained. There were 9 males and 4 females (see Table 1). The time since symptom onset
to serum/CSF sampling ranged from 7 to 41 months, median 14 months. Twelve patients had
typical Type 1 narcolepsy (CSF orexin deficient) first presenting post-H1N1 vaccination. Pa-
tient #12, a 24 year old man, developed narcolepsy 18 months pre-vaccination but his cataplexy
symptoms increased markedly following H1N1 vaccination.
All these subjects had the classical HLA DQB106:02 allele,
Antibodies to known neuronal surface antigens
None of the CSFs or sera showed IgG antibodies binding to NMDAR, CASPR2, LGI1, dopa-
mine receptors or GABAA α3 receptor (Table 1).
Antibodies to neuronal tissue
Antibody binding to the hypothalamus was found in four narcolepsy patient sera (Fig 1), and
not in the healthy control sera (data not shown), but this binding was not specific for orexin
neurons, since MCH-positive neurons were also stained (Fig 2A), and similar binding was de-
tected in other brain regions including the cortex and hippocampus (data not shown). None of
the narcolepsy CSFs showed detectable IgG binding to the rat brain sections.
MCH levels in CSF
CSF MCH levels were only measured in eight patients, and were variable but with a clear trend
towards higher values in the orexin negative narcolepsy CSFs compared with orexin normal
Fig 1. Binding of IgG from patients to orexin neurons on paraformaldehyde-fixed rat brain tissue
sections. Co-localisation of serum IgG binding and orexin immunoreactivity was optimised using
autoimmune disease and healthy control sera. In four marcolepsy patient sera, identified as reactive on the
initial immunofluorescence screen, the patient serum IgG binding co-localised with commercial antibody to
orexin, but there was also binding to other non-orexin neurons.
doi:10.1371/journal.pone.0129555.g001
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non-narcolepsy paediatric CSFs (p = 0.054, Student’s unpaired t-test; Fig 2B, Table 1) or adult
normal CSFs tested in parallel (data not shown).
Antibodies binding to live hippocampal neurons
None of the Type 1 narcolepsy patients were positive for binding to live hippocampal neurons,
cultured from new-born rat pups.
Serum IgG levels pre and post H1N1-AS03 vaccination
Total IgG levels were measured in sera from 42 healthy children [19] obtained pre and post-
vaccination with H1N1-AS03 (age range 6 months to 12 years, mean age 4.8 months). Al-
though the mean value post-vaccination was a little higher in the H1N1-AS03 vaccine recipi-
ents than prior to immunisation, this did not reach significance (p = 0.22; Fig 3A). To see if any
antigen-specific antibodies had been induced by the vaccination, CASPR2 and NMDAR anti-
bodies were measured. CASPR2 antibodies were insignificant (score<1) both pre- and post-
vaccination, but NMDAR antibodies were weakly positive in one child pre- and post-vaccina-
tion, and one other child post vaccination only (Fig 3B) though these low values would not nec-
essarily be considered of clinical relevance [22].
Discussion
The role of autoantibodies in narcolepsy has been of interest for many years but no disease spe-
cific, potentially pathogenic, antibodies have been identified. The existence of a post-vaccina-
tion form of narcolepsy offered an opportunity to examine sera and CSFs for the presence of
neuronal surface antibodies. Although no disease specific antibodies were found, four of 13
narcolepsy type 1 sera bound to orexin neurons, among other neurons, on brain tissue sections,
suggesting some increase in neuronal autoimmunity. However, there was no evidence of
Fig 2. A. Binding of IgG to orexin and MCH neurons and CSFMCH levels in narcolepsy patients. Co-
localisation of serum IgG binding (green), orexin immunoreactivity (red) and MCH immunorecativity (purple)
showed co-localization of IgG binding with both orexin and MCH neurons. B. MCHmeasurements in 8
available CSFs (including one without serum available) from post-H1N1-AS03-vaccinated orexin-deficient
narcolepsy children compared with CSFs from 6 orexin-normal children.
doi:10.1371/journal.pone.0129555.g002
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specific antibodies in the AS03-H1N1 vaccination samples, and similarly there was no clear in-
crease in autoimmunity or total IgG levels post-vaccination in the ASO3-H1N1 vaccination
trial samples, although the numbers studied were relatively small and not many would have
had the classical HLA DQB106:02 allele.
There have been many attempts [13] to identify antibody targets in narcolepsy, and others
have identified hypothalamic hormone peptides [23] or orexin neuron-specific transcripts [24]
that might prove to be narcolepsy-specific antibody targets, but immunostaining of rodent
brain here only showed antibody binding to brain tissue in four of the post-vaccination narco-
lepsy children, and the binding was not orexin-cell specific. The complete absence of CSF reac-
tivity with brain tissue sections or neuronal cultures was disappointing and could be
interpreted as lack of evidence for any antibody-mediated pathogenesis in these patients, but
since the immune response likely begins in the periphery the CSF levels could be very low and
not easily detectable unless, or until, substantial intrathecal synthesis of the antibody occurs.
Moreover, if the immune response rapidly destroyed the orexin/hypocretin neurons, antibod-
ies may no longer be detectable either centrally or peripherally in samples such as these collect-
ed some months after the onset of narcolepsy symptoms.
The MCH neurons, which are normally interspersed between the orexin neurons and pro-
mote sleep, are not thought to be affected in narcolepsy [3]. A recent publication reported anti-
bodies to a shared C terminal peptide of glutamic acid-isoleucine/a-melanocyte stimulating
hormone (NE1/aMSH) which could alter MCH neuron functions in patients with narcolepsy
[23], suggesting that secretion of the MCH peptide might be altered. Here, MCH levels in CSFs
from orexin-deficient narcolepsy children showed a trend towards higher levels (p = 0.054)
than in CSFs from orexin-normal children, although raised levels were not previously found in
14 patients with narcolepsy [25].
Fig 3. Results of total IgG and specific neuronal antibodies in available samples from pre and post-
AS03-H1N1 vaccination study. The NMDAR antibody scores were not different between the pre- and post-
vaccine patients although there were low positive results (scores 1 and 1.5) in two children post-vaccination.
None of the CASPR2 antibodies reached the threshold score of 1 even though the average binding was
slightly higher post-vaccine.
doi:10.1371/journal.pone.0129555.g003
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The study has obvious limitations. The number of subjects studied was small. Further candi-
date antigens or membrane proteins expressed in orexin cells could be explored further in the
future. Unfixed tissue might provide a more suitable substrate than fixed brain sections to de-
tect antibodies binding to highly conformational membrane proteins. To demonstrate cell-sur-
face binding, use of live orexin-neurons would clearly be preferable to hippocampal neurons,
but this would require further development.
Although the binding to brain tissue found in 4/13 patients may represent an increase in
autoreactivity, this could occur as a secondary phenomenon following a T cell or other immune
attack on the orexin neurons. Nevertheless, these studies did not exclude the possibility of a
highly specific antibody, and as antibody-mediated diseases are usually responsive to immuno-
therapies [14] the topic remains an important area for future study.
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